个人简介
1984年生人,汉族,现为中央民族大学药学院教师。从事民族药学及药理毒理学研究,主要研究方向为糖尿病及其并发症发病机制与中药/民族药干预研究。主持国家自然科学基金青年基金项目1项,在Clin Transl Med、J Ethnopharmacol、Ecotoxicol Environ Saf、中草药(英文版)、中国新药杂志等国内外学术期刊上发表论文20余篇,出版专著1部;获授权发明专利1项。
个人教育经历
2003.09-2007.06 大连医科大学 药学 理学学士
2007.09-2010.06 大连医科大学 微生物与生化药学 医学硕士
2010.07-2013.06 中央民族大学 中国少数民族传统医学 法学博士
研究领域
从事民族药学及药理毒理学研究,主要研究方向为糖尿病及其并发症发病机制与中药/民族药干预研究
近期论文
查看导师最新文章
(温馨提示:请注意重名现象,建议点开原文通过作者单位确认)
Zhang YJ, Zhang YS, Yao RF, He X, Zhao LY, Zuo XY, Lu BN * and Pang ZR*. Ferroptosis-related DEGs serve as new biomarkers in ischemic stroke and identification of therapeutic drugs. Frontiers in Nutrition 2022; 9:1010918. (A+,IF=6.576)
Zhang Y#, Fan L#, Yao R, He X, Zhao L, Lu B* and Pang Z*. ACEs family genes: Important molecular links between lung cancer and COVID-19. Clin Transl Med. 2021; 11(12): e615. (A+,IF=11.492)
Zhang YJ, Zhao LY, He X, Yao RF, Lu F, Lu BN* and Pang ZR*. CBXs-related prognostic gene signature correlates with immune microenvironment in gastric cancer. Aging (Albany NY). 2022; 14(15):6227-6254. (A,IF=5.682)
Niu H#, Fan L#, Zhao L, Yao R, He X, Lu B* and Pang Z*. The therapeutic mechanism of PuRenDan for the treatment of diabetic nephropathy: Network pharmacology and experimental verification. J Ethnopharmacol. 2022; 293:115283. (A,IF=4.36)
Fan L, Niu H, Zhao L, Yao R, He X, Lu B*and Pang Z*. Purendan alleviates non-alcoholic fatty liver disease in aged type 2 diabetic rats via regulating mTOR/S6K1/SREBP-1c signaling pathway. Biomed Pharmacother. 2022; 148:112697. (A,IF=6.53)
Guo R, Lv J, Xu H, Bai Y, Lu B* and Han Y*. A systems toxicology approach to explore toxicological mechanisms of fluoroquinolones-induced testis injury. Ecotoxicol Environ Saf. 2021; 228:113002. (A,IF=6.291)
Zhang Y, Wei H, Fan L, Fang M, He X, Lu B* and Pang Z*. CLEC4s as Potential Therapeutic Targets in Hepatocellular Carcinoma Microenvironment. Front Cell Dev Biol. 2021; 9: 681372. (A,IF=6.684)